US · Healthcare · Biotechnology
EPS came in at -1.07 against a street estimate of -1.54 — a beat of 30.5%.
Analysts rate Korro Bio, Inc. a strong buy (9 buy, 1 hold, 0 sell out of 10) with an average price target of $20.20.
| Fund | Stake |
|---|---|
| Lynx1 Capital Management, LP | 10.45% |
| Nantahala Capital Management, LLC | 8.96% |
| NEA Management Company, LLC | 8.81% |
| VR Adviser, LLC | 6.86% |
| Atlas Venture Life Science Advisors, LLC | 6.54% |
| Balyasny Asset Management LLC | 6.46% |
| BlackRock Inc | 5.55% |
| Affinity Asset Advisors, LLC | 4.80% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Korro Bio, Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.